Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 35
01
Overview
A Phase 3 trial of maridebart cafraglutide in heart failure with preserved ejection fraction (HFpEF), heart failure with mildly reduced ejection fraction (HFmrEF), obesity, sponsored by Amgen. Started Jun 2025; status: recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mildly reduced ejection fraction (HFmrEF)obesity
Beyond the preview
Go deeper on NCT07037459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07037459.